相关实验视频

Updated: Jun 12, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

奎萨提尼布:急性髓性白血病的新希望,应用综合性审查

Fatemeh Esmaeilpour Moallem¹, Mohammad Sadra Gholami Chahkand¹, Parisa Alsadat Dadkhah²

¹Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran.

Future oncology (London, England)

|September 19, 2024

概括

奎萨丁尼布有效地向了急性髓性白血病 (AML) 中的FMS类型的铁酶-3 (FLT3) 突变. 本综述详细介绍了FLT3突变AML患者的机制,疗效和临床应用.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

急性髓性白血病 (AML) 的发病过程涉及恶性克隆扩张,通常是由FMS类型的氨酸激酶-3 (FLT3) 突变驱动的.
在FLT3中,内部串联重复 (ITD) 是一种常见的突变,与AML的不良预后有关.
针对性治疗对于改善复发性/耐药性AML与特定突变的结果至关重要.

研究的目的:

审查一种强大的FLT3抑制剂Quizartinib的作用机制.
评估Quizartinib在AML单疗法和联合疗法中的疗效.
讨论药物相互作用,不良事件,耐药性机制以及Quizartinib的未来研究方向.

主要方法:

关于Quizartinib的临床研究和研究的文献综述.
对Quizartinib的药理特性和临床试验数据的分析.
探索抵抗机制和潜在的治疗策略.

主要成果:

奎萨提尼布显示出强大的FLT3抑制,口服吸收优异.
临床研究表明,Quizartinib在治疗FLT3/ITD突变的复发性/耐药性AML方面具有前景.
了解不良事件和耐药性是优化Quizartinib治疗的关键.

结论:

奎萨丁尼布是FLT3突变AML的重要治疗选择.
需要进一步的研究,以充分阐明Quizartinib在组合疗法和克服耐药性的作用.
持续的研究将完善FLT3突变的AML患者的治疗策略.

关键词:

在AML,AML就是AML.这是一种FLT3抑制剂.在 FLT3-ITD 突变中.恶性瘤是一种恶性瘤.奇萨丁尼布 (quizartinib) 是一种药物.

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...